Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-90006 in healthy subjects
NCT02934269Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2016
- Primary completion
- Aug 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CC-90006 in psoriasis (6 arms), sponsored by Celgene Corporation. Primary endpoint: Adverse Events (AEs). Started Nov 2016; status: completed.
02
Drugs
CC-90006
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT02934269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02934269.